The pharmacokinetics of intranasal droperidol in volunteers characterised via population modelling

Cooper, Isabelle; Landersdorfer, Cornelia B.; John, Ashley Gordon St; Graudins, Andis

doi:10.1177/2050312118813283

Cited by 3 publications

(2 citation statements)

References 17 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…It has been shown that low dose intranasal (IN) droperidol has a peak serum level within 1 h of administration and that it approximates the levels reached using low dose i.v. droperidol 8 …”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Patients treated for acute headache with intranasal droperidol spend less time in the emergency department: A retrospective observational study

Stern

Munro

King

et al. 2022

Emerg Medicine Australasia

View full text Add to dashboard Cite

Objective Headache is a common presenting complaint to the ED. Using time from the first provider to discharge as a surrogate for effectiveness, we aimed to determine if intranasal (IN) droperidol is as beneficial as usual treatment for acute headache in the ED. Methods There were 1213 consecutive presentations of adults with acute headache over a 42‐month period. Electronic records for each event were interrogated, 406 events met pre‐determined exclusion criteria. Of the remaining 805 eligible patient events, 139 received IN droperidol, whereas 666 were given usual therapy. Results There was a 20 min reduction of mean and median ED length of stay (LOS) for the group that got treated with IN droperidol. Conclusions IN droperidol reduced LOS in the ED. There are potential cost savings of this effective treatment via this novel route. A prospective multi‐centre study of the use of IN droperidol for the treatment of acute headache in the ED is recommended.

show abstract

Section: Introductionmentioning

confidence: 99%

“…droperidol. 8 Our department has been successfully using IN droperidol to treat headache for several years. To our knowledge, there have been no published studies of IN droperidol for the treatment of any disease.…”

Section: Introductionmentioning

confidence: 99%

Patients treated for acute headache with intranasal droperidol spend less time in the emergency department: A retrospective observational study

Stern

Munro

King

et al. 2022

Emerg Medicine Australasia

View full text Add to dashboard Cite

show abstract

Influence of antipsychotic medications on hyperlipidemia risk in patients with schizophrenia: evidence from a population-based cohort study and in vitro hepatic lipid homeostasis gene expression

Tien

Lin

et al. 2023

Front. Med.

View full text Add to dashboard Cite

IntroductionSchizophrenia increases the risk of mortality and cardiovascular disease (CVD) risk. However, the correlation between antipsychotics (APs) and CVD remains controversial. Hyperlipidemia is a significant risk factor for CVD.MethodsWe conducted a nationwide population-based retrospective cohort study to investigate the effects of APs on the risk of hyperlipidemia and lipid homeostasis gene expression. We used data from the Longitudinal Health Insurance Database of Taiwan on new-onset schizophrenia patients and a comparison cohort without schizophrenia. We used a Cox proportional hazards regression model to analyze the differences in hyperlipidemia development between the two cohorts. Furthermore, we examined the effects of APs on the hepatic expression of lipid homeostasis-related genes.ResultsAfter adjusting for potential interrelated confounding factors, the case group (N = 4,533) was found to have a higher hyperlipidemia risk than the control cohort (N = 4,533) [adjusted hazard ratio (aHR), 1.30, p < 0.001]. Patients with schizophrenia without APs had a significantly higher risk of hyperlipidemia (aHR, 2.16; p < 0.001). However, patients receiving APs had a significantly lower risk of hyperlipidemia than patients not receiving APs (all aHR ≤ 0.42, p < 0.001). First-generation antipsychotics (FGAs) induce the expression of hepatic lipid catabolism genes in an in vitro model.DiscussionPatients with schizophrenia had a higher risk of hyperlipidemia than controls; however, compared with non-treated patients, AP users had a lower risk of hyperlipidemia. Early diagnosis and management of hyperlipidemia may help prevent CVD.

show abstract

Haloperidol for Pain Management: A Narrative Review

Roldan,

Rowland,

2024

Pharmaceuticals

View full text Add to dashboard Cite

The use of haloperidol in pain management has been a topic of interest for several decades. Haloperidol is a widely used antipsychotic medication with unique pharmacologic properties that make it a potential candidate for pain management. However, the efficacy and safety of haloperidol for pain management remain controversial. This narrative review provides a summary of the current literature on the use of haloperidol for pain management, including its pharmacology, clinical effectiveness, adverse effects, and dosing regimens. We performed a comprehensive search of the literature for this review. The most robust clinical data from the past decade suggest that haloperidol has good efficacy in the treatment of pain related to gastroparesis and migraines and has shown promise for opioid use reduction in patients with chronic pain or receiving palliative care. The overall side effect profile is excellent, with zero reported events of QT-related cardiac arrest and minimal reports of sedation and transient extrapyramidal effects such as akathisia. Dosing regimens used were heterogeneous, with most ranging from 1 to 5 mg per dose via intravenous, intramuscular, or oral route. Studies with designs that isolated the effects of haloperidol from combinations of other drugs were extremely limited. Further high-quality prospective studies are needed to determine the ideal role of haloperidol in the routine clinical management of painful conditions.

show abstract

The pharmacokinetics of intranasal droperidol in volunteers characterised via population modelling

Cited by 3 publications

References 17 publications

Patients treated for acute headache with intranasal droperidol spend less time in the emergency department: A retrospective observational study

Patients treated for acute headache with intranasal droperidol spend less time in the emergency department: A retrospective observational study

Influence of antipsychotic medications on hyperlipidemia risk in patients with schizophrenia: evidence from a population-based cohort study and in vitro hepatic lipid homeostasis gene expression

Haloperidol for Pain Management: A Narrative Review

Contact Info

Product

Resources

About